Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Gains from Investment Securities (2019 - 2022)

Historic Gains from Investment Securities for C4 Therapeutics (CCCC) over the last 4 years, with Q1 2022 value amounting to $44.1 million.

  • C4 Therapeutics' Gains from Investment Securities rose 64025.93% to $44.1 million in Q1 2022 from the same period last year, while for Dec 2022 it was $44.1 million, marking a year-over-year change of. This contributed to the annual value of $44.1 million for FY2022, which is 11890.12% up from last year.
  • According to the latest figures from Q1 2022, C4 Therapeutics' Gains from Investment Securities is $44.1 million, which was up 64025.93% from $20.1 million recorded in Q4 2021.
  • Over the past 5 years, C4 Therapeutics' Gains from Investment Securities peaked at $44.1 million during Q1 2022, and registered a low of $2.3 million during Q4 2019.
  • Over the past 4 years, C4 Therapeutics' median Gains from Investment Securities value was $5.9 million (recorded in 2021), while the average stood at $11.3 million.
  • In the last 5 years, C4 Therapeutics' Gains from Investment Securities soared by 969.82% in 2020 and then surged by 69412.23% in 2021.
  • C4 Therapeutics' Gains from Investment Securities (Quarter) stood at $2.3 million in 2019, then grew by 9.7% to $2.5 million in 2020, then skyrocketed by 694.12% to $20.1 million in 2021, then skyrocketed by 118.9% to $44.1 million in 2022.
  • Its Gains from Investment Securities was $44.1 million in Q1 2022, compared to $20.1 million in Q4 2021 and $5.9 million in Q3 2021.